Please assess the completion status of the following clinical trial:

Trial Title: Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib~* Karnofsky ≥ 50% for patients \> 10 years of age and Lansky ≥ 50 for patients ≤ 10 years of age~* Adequate renal, hepatic and pancreatic function~* Potassium, magnesium, phosphorus and total calcium values ≥ LLN (lower limit of normal)~* Written informed consent~Key Exclusion Criteria:~* Treatment with strong CYP3A4 inhibitors or inducers~* Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval~* Acute or chronic liver, pancreatic or severe renal disease~* History of pancreatitis or chronic pancreatitis.~* Impaired cardiac function~* No evidence of active graft vs host and \<3mo since Stem Cell Transplant~* Total body irradiation (TBI) or craniospinal radiation therapy \<6months~* Hypersensitivity to the active ingredient or any of the excipients including lactose.~* the criteria regarding pregnancy and contraception~* Active or systemic bacterial, fungal, or viral infection~* known Hepatitis B, Hepatitis C, or HIV infection

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Newly diagnosed and untreated Ph+ CML in first CP (Type: EXPERIMENTAL): Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
- Resistant/intolerant Ph+ CML in CP (Type: EXPERIMENTAL): Resistant or Intolerant to either imatinib or dasatinib
- Resistant/intolerant Ph+ CML in AP (Type: EXPERIMENTAL): Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).